Oyster Therapeutics is a pharmaceutical company based in London developing targeted protein degraders, with an initial focus on tau-driven neurodegenerative diseases such as Alzheimer's. Its proprietary SELFTAC platform is designed to address the size limitations of conventional bifunctional targeted protein degraders. The company was previously known as Kesmalea Therapeutics.
Oyster Therapeutics: Venture Capital Funding History
Oyster Therapeutics
Oyster Therapeutics
- Life Sciences
- London, United Kingdom
- £45m
- oyster-tx.com
- Update Information
More venture news
- 13 Nov 2026
Oyster TherapeuticsOyster Therapeutics secures a £45m Series A round from CE-Ventures to develop an oral drug for neurodegenerative diseases
Series ALife Sciences - 10 Nov 2026
Neobe TherapeuticsNeobe lands a £5m seed round led by ARC Ventures to deliver cancer drugs directly into solid tumours
SeedLife Sciences - 9 Nov 2026
PhaSER BiomedicalPhaSER Biomedical secures a £2m grant from Gates Foundation to discover new treatments for neglected diseases
GrantLife Sciences
